Genetic mutations in metastatic adenocarcinoma of unknown primary.
Summary
This study analyzed the genomic profile of 480 patients with metastatic adenocarcinoma of unknown primary (ACUP) using the FoundationOne CDx platform. The most frequent mutations included TP53, KRAS, and CDKN2A. Results showed that GNAS and PIK3CA mutations were associated with better overall survival. Conversely, ARID1A and NOTCH1 alterations were linked to a worse prognosis. These findings highlight the significance of specific genomic alterations as prognostic markers in ACUP.
Analysis
This research is crucial as it sheds light on specific genomic prognostic markers in adenocarcinoma of unknown primary, a disease often challenging to manage due to its heterogeneity. Integrating comprehensive genomic profiling (CGP) into clinical practice could enable better risk stratification and potentially guide future therapeutic decisions, even if specific targeted therapies are not yet established. Identifying mutations associated with favorable or unfavorable prognoses provides avenues for clinical trials and precision medicine.